GSTM1 and stage 5 chronic kidney disease: Participants with CRAS displayed a higher likelihood for both end-stage renal disease (ESRD) (eGFR < 15) and the severe form of anemia (Hb < 8 g/dL) compared to their non-CRAS counterparts with renal dysfunction or anemia, (both p < 0.001).